Compare ACADIA Pharmaceuticals Inc. (ACAD) vs MobilEye Global Inc (MBLY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs MobilEye Global Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.79 (market cap $4.49B), while MobilEye Global Inc trades at $8.92 (market cap $8.00B). The key difference: MobilEye Global Inc is the larger of the two by market cap, and ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, MobilEye Global Inc nearer its low. Which is the better fit depends on your goals.
| ACAD | MBLY | |
|---|---|---|
Market Cap | $4.49B | $8.00B |
Sector | Health | Technology |
52-Week High | $28.06 | $18.64 |
52-Week Low | $20.06 | $6.56 |
Enterprise Value | $3.69B | $6.66B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
Mobileye (MBLY) trades at $10.00, up 4.49% today, with a bullish technical signal from moving averages and strong analyst support. The stock shows negative profitability with a net income margin of -203.97% in 2026 but maintains solid revenue growth, reaching $2.0B. Recent news highlights its strategic shift to launch a vertically integrated U.S. robotaxi service in 2027, positioning it against competitors like Waymo and Tesla.
The outlook is cautiously optimistic due to the robotaxi initiative's potential, but high execution risks and persistent losses pose challenges. Analysts project a consensus price target of $10.36, with 57.69% recommending Buy. Investors should weigh the growth opportunity against the company's current unprofitability and competitive pressures in the autonomous vehicle sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About MobilEye Global Inc
Mobileye Global Inc. is a global leader in the development and deployment of Advanced Driver Assistance Systems (ADAS) and autonomous driving technologies. The company specializes in computer vision, machine learning, and data analysis to create sensing, mapping, and driving policy solutions. Mobileye's technology, including its EyeQ system-on-chips and its crowd-sourced mapping platform (REM), is integrated into vehicles worldwide, aiming to improve road safety and enable the future of autonomous mobility.
Read more on MBLY →
